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time may be more inﬂuential, but more research is needed to
ensure appropriate consideration and valuation of leisure.
PATIENT REPORTED OUTCOMES
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OBJECTIVES: The aim of this study was to describe the health
related quality of life (HRQoL) in different breast cancer disease
states using preference-based measures. METHODS: A total of
361 consecutive breast cancer patients attending the breast
cancer outpatient clinic at Karolinska University hospital Solna
for outpatient visits between April and May 2005 were included
in the study. The EQ-5D self classiﬁer and a direct Time Trade
Off (TTO) question was used to estimate the HRQoL in differ-
ent breast cancer disease states. RESULTS: All of the different
disease states had lower HRQoL compared to the general pop-
ulation. Patients in their ﬁrst year after a primary breast cancer
had a mean EQ-5D index value of 0.696 (95% conﬁdence 
interval (CI): 0.634–0.747)). Patients in their ﬁrst year after a
recurrence had a mean EQ-5D index value of 0.779 (CI:
0.700–0.849). Patients whom had not had a primary breast
cancer diagnosis or a recurrence during the previous year had a
mean EQ-5D index value of 0.779 (CI: 0.745–0.811). Patients
with metastatic disease reported the lowest HRQoL values, and
had a mean EQ-5D index value of 0.685 (CI: 0.620–0.735). The
main driver behind the reduction in HRQoL was pain and dis-
comfort as well as anxiety and depression. TTO values were
higher for all diseases states compared to the EQ-5D index
values. CONCLUSION: This study shows that breast cancer is
associated with a reduction in HRQoL. This effect is most pro-
nounced for patients with metastatic disease. Our results also
indicate that breast cancer has a permanent negative effect on
HRQoL, even if the patient remains recurrence free.
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OBJECTIVES: A new utility index derived of the SF-36, the SF-
6D, was recently developed and has generated an increasing
research in different groups of patients and has also been com-
pared with other utility measures, as it is the EQ-5D. The
purpose of the present work is to validate this index in the
Spanish version of SF-36 with respect to the Spanish version of
the EQ-5D. METHODS: A total of 1843 complete measures of
the SF-36 (version 2) and the EQ-5D (5 items and visual ana-
logic scale-VAS) from 1283 patients who received a solid organ
transplant (kidney, liver, heart or lung) were used. Data were col-
lected at different moments during the ﬁrst year after the surgery
in the context of the Spanish Research Network on Transplan-
tation. SF-6D values were calculated using the model proposed
by its creator. EQ-5D values were calculated using Spanish VAS
tariff (VAS-t) and time-trade off tariff (TTO-t). Spearman corre-
lation coefﬁcients were calculated between SF-6D and EQ-5D
values. RESULTS: Mean value (SD) of SF-6D was 0.67 (0.15)
(range 0.3–1.0), of EQ-5D VAS-t, 0.69 (0.24) (range −0.08–1.0)
and of TTO-t, 0.70 (0.32) (range −0.7–1). Percentage of subjects
scoring the maximum was 1.1% for SF-6D, and 24.5% for the
EQ-5D. SF-6D values had moderate correlation with EQ-5D
VAS-t (r = 0.734) and EQ-5D TTO-t (r = 0.731) (both p < 0.001).
CONCLUSIONS: The SF-6D index derived from the Spanish
version of SF-36 seem to be a valid utility index to be used with
the SF-36 databases from studies made in Spain. However the
moderate correlation between both utility measures indicates
that probably they partially measure different concepts.
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OBJECTIVE: Lack of adherence with gastroprotective agents
(GPAs) when prescribed with non-selective (ns) NSAIDs may
increase risk of hospitalisation for gastrointestinal (GI) condi-
tions. This study assessed the effect of frequent nsNSAID use
with varying levels of GPA use on GI outcomes. METHODS:
Prescription data from a primary care database (DIN-LINK),
representative of the UK population, containing records of over
800,000 patients, was used. Patients with osteoarthritis and/or
rheumatoid arthritis who received nsNSAID therapy and co-
prescribed GPA between September 2003 and August 2005 
were identiﬁed. Adherence (proportion of days covered (%)) at
monthly intervals was deﬁned as days on gastroprotective
therapy within a moving window of three consecutive months
on nsNSAID. Patients were assessed according to their level of
GPA use (0–19, 20–39, 40–59, 60–79, 80–99, 100%). Records
of hospitalisation for GI conditions (also available in the data-
base) at monthly intervals were analysed as a function of GPA
adherence. Odds ratios of GI-related hospitalisation between
cohorts of varying GPA use were calculated. Additional analysis
was performed according to GI risk factors. RESULTS: The data-
base identiﬁed 15,956 patients with an NSAID prescription for
at least 75% of the examined period, and of these, 8890 patients
with a GPA co-prescription with at least 20% use. The rate of
GI-related hospitalisation for the deﬁned period was 2.49% with
full (100%) GPA use. The odds ratio for GI related hospitalisa-
tion of the sub-cohorts vs. that with 100% adherence (95% 
CI), in decreasing order according to adherence, was 1.57
(1.14–2.16), 1.49 (0.95–2.36), 2.85 (1.84–4.43), 3.52
(2.28–5.44), 1.47 (1.19–1.81). The odds of GI-related hospital-
isation were up to 3.5 times higher for NSAID users with poorer
GPA adherence. CONCLUSION: Analysis of observational clin-
ical and prescription data revealed that the lower the GPA use
of frequent NSAID users, the higher the rates of hospitalisation
for GI conditions.
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OBJECTIVE: To elicit single-index preferences from people 
with diabetes for treatment with inhaled insulin compared to
injectable insulin. METHODS: Written descriptions were devel-
oped for ﬁve clinical scenarios in Type 1 and Type 2 diabetes
(T1D and T2D): 1) pre-mixed insulin in T1D; 2) basal-bolus
insulin in T1D; 3) pre-mixed insulin in T2D; 4) oral treatment
in T2D; and 5) oral treatment plus basal insulin in T2D. In each
scenario, adjustment or initiation of insulin treatment was
